Su En Ben - Net Worth and Insider Trading
Su En Ben Net Worth
The estimated net worth of Su En Ben is at least $1.6 Billion dollars as of 2024-09-27. Su En Ben is the Director of Getein Biotech Inc and owns about 201,670,300 shares of Getein Biotech Inc (SHSE:603387) stock worth over $1.6 Billion. Details can be seen in Su En Ben's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Su En Ben has not made any transactions after 2019-05-21 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Su En Ben
Su En Ben Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Su En Ben owns 1 companies in total, including Getein Biotech Inc (SHSE:603387) .
Click here to see the complete history of Su En Ben’s form 4 insider trades.
Insider Ownership Summary of Su En Ben
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| SHSE:603387 | Getein Biotech Inc | 2019-05-21 | Director |
Su En Ben Latest Holdings Summary
Su En Ben currently owns a total of 1 stock. Su En Ben owns 201,670,300 shares of Getein Biotech Inc (SHSE:603387) as of May 21, 2019, with a value of $1.6 Billion.
Latest Holdings of Su En Ben
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| SHSE:603387 | Getein Biotech Inc | 2019-05-21 | 201,670,300 | 8.04 | 1,621,429,212 |
Holding Weightings of Su En Ben
Su En Ben Form 4 Trading Tracker
According to the SEC Form 4 filings, Su En Ben has made a total of 0 transactions in Getein Biotech Inc (SHSE:603387) over the past 5 years. The most-recent trade in Getein Biotech Inc is the sale of 57,620,085 shares on May 21, 2019, which brought Su En Ben around $0.
Insider Trading History of Su En Ben
- 1
Su En Ben Trading Performance
GuruFocus tracks the stock performance after each of Su En Ben's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Su En Ben is -12.76%. GuruFocus also compares Su En Ben's trading performance to market benchmark return within the same time period. The performance of stocks bought by Su En Ben within 3 months outperforms 0 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Su En Ben's insider trading performs compared to the benchmark.
Performance of Su En Ben
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -6.1 | | | | | |
| Relative Return to S&P 500(%) | -7.31 | | | | | |
Su En Ben Ownership Network
Ownership Network List of Su En Ben
Ownership Network Relation of Su En Ben
Su En Ben Owned Company Details
What does Getein Biotech Inc do?
Who are the key executives at Getein Biotech Inc?
Su En Ben is the Director of Getein Biotech Inc.
Getein Biotech Inc (SHSE:603387) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Getein Biotech Inc (SHSE:603387) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Getein Biotech Inc (SHSE:603387) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Getein Biotech Inc (SHSE:603387)'s detailed insider trading history can be found in Insider Trading Tracker table.
Getein Biotech Inc Insider Transactions
Su En Ben Mailing Address
Above is the net worth, insider trading, and ownership report for Su En Ben. Currently GuruFocus does not have mailing address information for Su En Ben.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
